- Clinical Trials
- April 2024
- 60 Pages
Global
From €1214EUR$1,250USD£1,047GBP
- Report
- January 2022
- 200 Pages
Global
From €7284EUR$7,500USD£6,284GBP
- Drug Pipelines
- March 2021
Global
From €1943EUR$2,000USD£1,676GBP
- Drug Pipelines
- July 2020
- 83 Pages
Global
From €1943EUR$2,000USD£1,676GBP
- Drug Pipelines
- June 2021
- 96 Pages
Global
From €3399EUR$3,500USD£2,933GBP
- Drug Pipelines
- August 2018
- 78 Pages
Global
From €3399EUR$3,500USD£2,933GBP
The Central Nervous System (CNS) Drug market is a subset of the pharmaceutical industry that focuses on the development and commercialization of drugs that target the central nervous system. These drugs are used to treat a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, depression, anxiety, and schizophrenia. CNS drugs are typically administered orally, intravenously, or intramuscularly.
The CNS Drug market is highly competitive, with a number of large pharmaceutical companies vying for market share. Companies such as Pfizer, Merck, GlaxoSmithKline, Novartis, and Eli Lilly are all major players in the CNS Drug market. Additionally, there are a number of smaller, specialty pharmaceutical companies that focus on developing and marketing CNS drugs. These companies include Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more
